Figure 3.

Ectopic Expression of ALK Stimulated the PI3K/AKT Pathway and BRAFi-Resistant Melanoma Showed Genetic Signatures Consistent with ALK Activation

(A) Parental and BRAF inhibitor (BRAFi)-resistant A375, SKMEL-239, and M229 cells were analyzed for the indicated protein by immunoblotting. ACTINB was used as the loading control.

(B) A375, M229, and SKMEL-28 cells ectopically expressing an empty vector or ALK were analyzed by western blot for the indicated proteins. ACTINB was used as the loading control.

(C) A375 parental (A375-P) cells, A375 BRAFi-resistant cells (A375-R), and A375-R cells treated with ceritinib (1 μM) for 24 h were analyzed by immunoblotting for the indicated proteins. ACTINB was used as the loading control.

(D) mRNA expression for the indicated ALK-activated genes was measured in A375-P, A375-R, and A375-R cells treated with ceritinib (1 μM) for 24 h. mRNA expression for indicated genes relative to A375-P cells is shown. ACTINB mRNA expression was used for normalization.

Data are presented as mean ± SD. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, respectively. See also Figures S2 and S3.